Information Provided By:
Fly News Breaks for January 31, 2020
Jan 31, 2020 | 08:03 EDT
JPMorgan analyst Cory Kasimov raised his price target for Vertex Pharmaceuticals to $260 from $247 and maintains an Overweight rating on the shares following the company's Q4 results. With Trikafta off to such an impressive start and multiple pipeline assets coming into focus over the course 2020, Vertex continues to offer "something for generalists and specialists alike," Kasimov tells investors in a research note.